youtube.com
Final Trades: Vertex Pharma, Kimberly-Clark, S&P Global and Exxon Mobil
The Investment Committee give you their top stocks to watch for the second half.
Vertex, Inc.VERXNASDAQ
LOADING
|||
Latest News
Loading news...
defenseworld.net
Critical Survey: Pcs Edventures!.Com (OTCMKTS:PCSV) and Vertex (NASDAQ:VERX)
Vertex (NASDAQ: VERX - Get Free Report) and Pcs Edventures!.Com (OTCMKTS:PCSV - Get Free Report) are both computer and technology companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends. Profitability This table compares Vertex and Pcs
businesswire.com
Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Fourth Quarter 2025 Earnings Call.” The conference call will be webcast live and a lin.
defenseworld.net
Vertex, Inc. (NASDAQ:VERX) Short Interest Update
Vertex, Inc. (NASDAQ: VERX - Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totaling 7,266,393 shares, an increase of 20.6% from the December 15th total of 6,023,811 shares. Based on an average daily volume of 1,022,407 shares, the
businesswire.com
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced business and program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT. “2025 was a year of strong commercial execution and rapid R&D progress, setting up the company for continued growth and many important milestones in 2026,” said Reshma Ke.
seekingalpha.com
Vertex Pharmaceuticals: Prepared To Defend Their Dominance And Expand Their Expertise
Vertex Pharmaceuticals remains a 'Top Idea' with robust Q3 earnings, a dominant CF franchise, and a broadening late-stage pipeline. VRTX's diversification into pain, kidney, cell, and gene therapies positions it for multiple launches between 2026–2028, supporting long-term growth. Financial strength is evident with $12B in cash, upgraded 2025 revenue guidance ($11.9B–$12B), and accelerating commercial momentum across new franchises.
defenseworld.net
Vertex, Inc. (NASDAQ:VERX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Vertex, Inc. (NASDAQ: VERX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eighteen analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and twelve have assigned a buy recommendation to the company.
fool.com
Why a 63% Vertex Selloff Didn't Scare Off a New $13 Million Investor
New York City-based Hyperion Capital Advisors initiated a stake in Vertex during the third quarter, buying up 540,000 shares. The shares were worth about $13.39 million at quarter-end.
businesswire.com
Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on.
defenseworld.net
Aperture Investors LLC Purchases 76,223 Shares of Vertex, Inc. $VERX
Aperture Investors LLC lifted its holdings in shares of Vertex, Inc. (NASDAQ: VERX) by 11.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 720,438 shares of the company's stock after buying an additional 76,223 shares during the period. Vertex
fool.com
Vertex Stock: Why One Fund Lifted Its $94.3 Million Position Even as Shares Sank
California-based Tensile Capital Management increased its position in Vertex by 160,559 shares in the third quarter. Despite the increase in shares, the position value fell by about $34.4 million from quarter to quarter.
fool.com
Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals?
Vertex Pharmaceuticals is the worldwide leader in cystic fibrosis treatment -- and its drugs have generated blockbuster revenue. The company has expanded into other therapeutic areas in recent years and has won approval for treatments for blood disorders and pain management.
reuters.com
Vertex's gene therapy shows promise in younger children with blood disorders
Vertex Pharmaceuticals said on Saturday its gene therapy helped children aged between 5 and 11 years with sickle cell disease to be free of painful events and allowed those with another blood disorder that requires frequent blood transfusions to be transfusion-free for at least 12 consecutive months.
businesswire.com
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with seve.
globenewswire.com
Vertex and CPA.com Announce AI-Driven Expansion of Tax Compliance Services for Accounting Firms
KING OF PRUSSIA, Pa., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, and CPA.com, the trusted partner in accounting and finance transformation, today announced an expansion of their partnership to include an AI-driven solution in collaboration with Kintsugi. The application helps accounting firms of all sizes and tax expertise deliver automated, accurate, and scalable sales tax compliance for clients.
fool.com
1 Reason I'll Never Sell Vertex Pharmaceuticals Stock
Vertex Pharmaceuticals dominates the cystic fibrosis treatment market and recently has expanded into other therapeutic areas. The biotech predicts full-year 2025 revenue of as much as $12 billion.
zacks.com
Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?
VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum.
defenseworld.net
Vertex, Inc. (NASDAQ:VERX) Given Average Rating of “Moderate Buy” by Analysts
Vertex, Inc. (NASDAQ: VERX - Get Free Report) has received an average recommendation of "Moderate Buy" from the eighteen analysts that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have given a buy rating to the company.
defenseworld.net
Bank of New York Mellon Corp Has $7.13 Million Stock Holdings in Vertex, Inc. $VERX
Bank of New York Mellon Corp lifted its stake in shares of Vertex, Inc. (NASDAQ: VERX) by 14.7% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 201,797 shares of the company's stock after purchasing an additional 25,812 shares during the
defenseworld.net
Bank Julius Baer & Co. Ltd Zurich Sells 51,003 Shares of Vertex, Inc. $VERX
Bank Julius Baer and Co. Ltd Zurich lowered its stake in Vertex, Inc. (NASDAQ: VERX) by 34.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 98,564 shares of the company's stock after selling 51,003 shares during the quarter.